Clinical Trial Update: Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 safety and preliminary efficacy study of PAT-SM6 in relapsed or refractory multiple myeloma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PAT-SM6

Snippet

Sponsor: Patrys Ltd. | Conditions: Drug Safety | Phase 1 | Status: COMPLETED